|Bid||0.1300 x 0|
|Ask||0.1350 x 0|
|Day's Range||0.1300 - 0.1400|
|52 Week Range||0.0450 - 0.2400|
|Beta (5Y Monthly)||1.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Total voting support agreements for the Transaction now represent 44.4%, or 162.7 million, of the total votes outstanding including all senior management and board membersShareholders to benefit from a global platform of premium and super premium brands and distribution through Canada, Israel and EuropeThe Transaction has been approved by an MYM Special Committee of Independent Directors Vancouver, British Columbia--(Newsfile Corp. - April 19, 2021) - MYM Nutraceuticals Inc. (CSE: MYM) (OTCQB: MYMMF) ("MYM" or ...
Highland Grow is currently profitable on an EBITDA basis and the Transaction is expected to be immediately accretive to IMCHighland Grow is expected to generate net revenue of $29 million and $38 million and gross margins of 34% to 36% in 2021 and 2022, respectivelyPurchase price implies 2.3x net revenue and 6.7x EBITDA in 2022 with synergiesMYM shareholders will receive 0.022 IMC shares for each MYM share, representing a price of $0.195 based on ...